TEST:

Agilent SureSelect Cancer CGP Assay

We demonstrated full customization capability of the SureSelect Cancer target enrichment platform that pairs user-defined content with an optimized probe design methodology to enable the sensitive detection of the common types of DNA alterations found in FFPE samples.

Second is a cost-effective method to investigate the homologous recombinant deficiency (HRD) status of solid tumor samples using the Agilent SureSelect Cancer CGP assay (targeting 679 genes). HRD status, a potential predictive biomarker for PARPi sensitivity, is demonstrated with two commercial informatics solutions.

"Agilent Technologies...announced the recent signing of a Memorandum of Understanding (MOU) with Theragen Bio in South Korea to boost precision oncology through advancing bioinformatic (BI) solutions. As part of the partnership agreement, Agilent and Theragen Bio will combine their respective strengths in cancer genomic profiling (CGP) design, engineering knowledge and software expertise to drive localized analysis capabilities and accelerate treatment decisions...Agilent’s SureSelect Cancer CGP assay uses next generation sequencing (NGS) to transform translational research and clinical trials in oncology through high throughput sequencing of DNA and RNA bases in parallel, while reducing hands-on time to maximize lab efficiency."

"Agilent Technologies...announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types. The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers. The assay workflow is efficient, automatable, and flexible, making tumor molecular profiling more accessible to the broad clinical research community."